A growing body of evidence

Key clinical outcomes support the use of the FreeStyle Libre Portfolio1-8,*

Lowered HbA1c1,3,*

Reduced avoidable resource utilization4,5,*

Reduced number of hypoglycemic events6,7,*

Reduced work absenteeism4,8,*

0.55%

average reduction observed in the first 2 months and sustained
over a 12-month period1,*,†

[95% CI; -0.70, -0.39]

The higher the initial HbA1c, the greater the reduction. No significant differences were seen based on study length, type of diabetes, or age.
“An Evaluation of Self-Management of Diabetes Using FreeStyle Libre Flash Glucose Monitoring System in Young People”

0.85%

average reduction
among patients with
T2D2,*,ǂ

P<0.0001

“Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients with Type 2 Diabetes”

0.4%

reduction among
children and teenagers
with T1D3,*

P<0.0001

“Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single-arm study”

66%

reduction in diabetes-related hospital admissions in T1D/T2D4,*

[187 (13.7%) to 32 (4.7%) at 12 months; P<0.05]

“Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)”

51%

reduction in acute diabetes events in
T2D5,*

P<0.001

“69-OR: Freestyle Libre System Use Is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes”

41%

reduction in number
of hypoglycemic
events for T1D6,*

[<55 mg/dL; −0.38/24-h day; P<0.0001]

“Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomized controlled trial”

44%

reduction in number
of hypoglycemic
events for T2D7,*

[<55 mg/dL; −0.12/24-h day; P=0.0017]

“Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial”

59%

reduction in work absenteeism among patients under 65 years old with T1D/T2D4,*

[18.5% to 7.7%; P<0.05]

“Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4)”

50%

reduction in
absenteeism among patients with T1D8,*

[5.8% to 2.9%; P<0.0001]

“Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study”

* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 system has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.
† A meta-analysis of RCTs and single arm studies (in addition to real world observational studies) on the impact of flash continuous glucose monitoring on glycemic control as measured by HbA1c.
ǂ vs SMBG.
§ For FreeStyle Libre 14 day system: Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
|| For FreeStyle Libre 2 system: Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first 12 hours.

References: 1. Yaron, Marianna, Eytan Roitman, Genya Aharon-Hananel, Zohar Landau, Tali Ganz, Ilan Yanuv, Aliza Rozenberg et al. “Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes.” Diabetes Care 42, no. 7 (2019): 1178-1184. 2. Evans, Mark, Zoë Welsh, Sara Ells, and Alexander Seibold. “The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies.” Diabetes Therapy 11, no. 1 (2020): 83-95. 3. Campbell, Fiona M., Nuala P. Murphy, Caroline Stewart, Torben Biester, and Olga Kordonouri. “Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study.” Pediatric Diabetes 19, no. 7 (2018): 1294-1301. 4. Fokkert, Marion, Peter van Dijk, Mireille Edens, Eglantine Barents, Jeanine Mollema, Robbert Slingerland, Reinold Gans, and Henk Bilo. “Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4).” BMJ Open Diabetes Research and Care 7, no. 1 (2019). https://doi.org/10.1136/bmjdrc-2019-000809. 5. Bergenstal, Richard M., Matthew SD Kerr, Gregory J. Roberts, Diana Souto, Yelena Nabutovsky, and Irl B. Hirsch. “69-OR: Freestyle Libre System Use Is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events and All-Cause Hospitalizations in Patients with Type 2 Diabetes.” (2020). Diabetes 69, no. Supplement 1 (2020). https://doi.org/10.2337/db20-69-or. 6. Haak, Thomas, Hélène Hanaire, Ramzi Ajjan, Norbert Hermanns, Jean-Pierre Riveline, and Gerry Rayman. “Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial.” Diabetes Therapy 8, no. 1 (2017): 55-73. 7. Bolinder, Jan, Ramiro Antuna, Petronella Geelhoed-Duijvestijn, Jens Kröger, and Raimund Weitgasser. “Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.” The Lancet 388, no. 10057 (2016): 2254-2263. 8. Charleer, Sara, Christophe De Block, Liesbeth Van Huffel, Ben Broos, Steffen Fieuws, Frank Nobels, Chantal Mathieu, and Pieter Gillard. “Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study.” Diabetes Care 43, no. 2 (2020): 389-397.

ADC-17131 v4.0 03/21